Pamela Hay provides interim management and strategic advisory services to biotech companies that are seeking to complete significant partnering or financing transactions. She has served as acting CEO or CBO and as a senior business advisor to management and investors during periods of transition and rapid growth. In these roles, she often leads the planning, diligence process and negotiation of strategic transactions.
She is a founding partner of Red Sky with 30 years of executive or advisory roles at numerous biotech companies spanning the start-up through Phase 3 product development stages in multiple therapeutic indications and modalities. Her recent Red Sky assignments include serving as acting CEO for Kera Therapeutics, interim CBO for Ribon Therapeutics, co-CEO of Harbour Antibodies (where she led its sale to Harbour Biomed), lead business negotiator for Luc Therapeutics in its Novartis CNS deal and interim CBO for Nimbus Therapeutics.
Previously, Pamela was Chief Commercial Officer of Domantis Ltd, a Cambridge UK biotech company, sold to GSK for $450m in 2007. She was SVP, Corporate Development at Dyax Corp, where she designed and implemented the company’s broad-based licensing and partnering programs for phage display IP and technology, resulting in over 75 business deals. Her earlier positions include General Counsel of T Cell Sciences and Corporate Attorney at Biogen.
Pamela has a BA in Biology from Cornell University’s School of Arts and Sciences, and a JD from the University of Wisconsin School of Law.